Related Articles |
Type 2 endoleak incidence and fate after EVAR in a multicentric series: different results with different devices?
Ann Vasc Surg. 2018 Nov 28;:
Authors: Sirignano P, Capoccia L, Mansour W, Ronchey S, Accrocca F, Siani A, Mangialardi N, Speziale F
Abstract
OBJECTIVES: Aim of this work is describing incidence and fate of type 2 endoleaks (T2EL) in a multi-centric cohort of patients treated by EVAR with Ovation device (Endologix), and compering them with a group treated by Excluder (W.L. Gore & Associates).
METHODS: retrospective study conducted on 261 patients treated by Ovation, and 203 by Excluder. Outcomes were intraprocedural, 30-day, 12-month, and mean time follow-up T2EL incidence and related reinterventions. Patent inferior mesenteric artery (IMA), ≥3 lumbar arteries (LAs), intrasac thrombus amount, mean common and external iliac arteries diameter, EIA stenosis (>70%), and diameter ≤5mm, iliac tortuosity ratio ≤0.5, thrombosis and calcification were noted, and considered as potentially influencing outcome.
RESULTS: Ovation group patients presented significantly more thrombosed, calcified and tortuous iliac vessels compared to Excluder group. No significant differences were noted in sac thrombosis, IMA, and LAs patency. At completion angiography, T2EL was evident in 57 Ovation and 46 Excluder patients (p=0.832). At 1-month, in 33 Ovation group, and 28 Excluder patients (p=0.726,). At 12-month and mean time (30.14months) follow-up, no differences were evident between two groups: p=0.940 and 0.951, respectively. Log-rank test showed that rate of T2EL related reintervention was not different between the two groups (p=0.46). Regarding anatomical characteristics, in no case a statistically significant difference was observed between patients presenting or not T2EL (p>0.05).
CONCLUSIONS: Data showed no significant difference in term of T2EL incidence between the two study groups, none of preoperative anatomical feature was found to be significantly associated with T2EL appearance.
PMID: 30502380 [PubMed - as supplied by publisher]
from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2QhVa41
No comments:
Post a Comment